
Takeda commits to advancing treatments for rare bleeding disorders and cancer
pharmafile | December 10, 2019 | News story | Manufacturing and Production, Research and Development | ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to advancing treatments for rare bleeding disorders.
These scientific updates from the company showed off investigational and early-stage therapies as well as data from Phase 3 trials in disease states like leukemia and lymphoma.
Phil Rowlands, Takeda’s head at the Oncology Therapeutic Area Unit, said: “We are presenting notable data on several clinical programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients.”
Takeda also presented its portfolio of treatments for rare bleeding disorders, including haemophilia A, B and von Wilibrand disease. It presented updates to its gene therapy programmes designed to deal with these types of diseases.
Daniel Curran, Head of Takeda’s Rare Diseases Therapeutic Area Unit, said: “Understanding real-world evidence is critical as Takeda continues to provide patients with innovative therapies for hemophilia A and hemophilia B while broadening our research and development efforts in von Willebrand disease and other bleeding disorders.”
Conor Kavanagh
Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …






